Skip to main content
. 2018 Jun 25;12:1137–1147. doi: 10.2147/OPTH.S160961

Figure 7.

Figure 7

BCVA and CMT over 2 years of treatment in eyes with and without baseline SRH (mean, SD).

Notes: *P<0.05. (A) Solid line: 10 eyes with baseline SRH. Mean BCVA (−0.0022) at 12 months and (0.013) at 24 months are significantly improved than initial mean BCVA (0.12) (paired t-test, P=0.003 and 0.008, respectively). Broken line: 29 eyes without baseline SRH. Mean BCVA (0.079) at 12 months and (0.084) at 24 months are not significantly different from initial mean BCVA (0.082) (paired t-test, P=0.3 and 0.4, respectively). (B) Solid line: mean CMT of eyes with baseline SRH significantly improved at 12 months (230 µm) and at 24 months (210 µm) than at baseline (350 µm) (paired t-test, P=0.02 and 0.009, respectively). Broken line: mean CMT of eyes without baseline SRH significantly improved at 12 months (250 µm) and at 24 months (250 µm) than at baseline (300 µm) (paired t-test, P=0.03 and 0.01, respectively). Change of logMAR BCVA at 12 months is −0.12 with SRH and −0.011 without SRH (P=0.02). The change of logMAR BCVA at 24 months is −0.010 with SRH and −0.0056 without SRH (P=0.06).

Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; logMAR, logarithm of minimum angle of resolution; PCV, polypoidal choroidal vasculopathy; SRH, subretinal hemorrhage.